Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 31:2018:1435302.
doi: 10.1155/2018/1435302. eCollection 2018.

Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres

C Bouvry  1   2 , X Palard  1   3 , J Edeline  1   4 , V Ardisson  1 , P Loyer  4 , E Garin  1   4 , N Lepareur  1   4
Affiliations
Review

Transarterial Radioembolization (TARE) Agents beyond 90Y-Microspheres

C Bouvry et al. Biomed Res Int. .

Abstract

Liver malignancies, either primary tumours (mainly hepatocellular carcinoma and cholangiocarcinoma) or secondary hepatic metastases, are a major cause of death, with an increasing incidence. Among them, hepatocellular carcinoma (HCC) presents with a dark prognosis because of underlying liver diseases and an often late diagnosis. A curative surgical treatment can therefore only be proposed in 20 to 30% of the patients. However, new treatment options for intermediate to advanced stages, such as internal radionuclide therapy, seem particularly attractive. Transarterial radioembolization (TARE), which consists in the use of intra-arterial injection of a radiolabelled embolising agent, has led to very promising results. TARE with 90Y-loaded microspheres is now becoming an established procedure to treat liver tumours, with two commercially available products (namely, SIR-Sphere® and TheraSphere®). However, this technology remains expensive and is thus not available everywhere. The aim of this review is to describe TARE alternative technologies currently developed and investigated in clinical trials, with special emphasis on HCC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
BCLC staging system and therapeutic strategy according to EASL-EORTC guidelines. © European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. (Adapted from J Hepatol 2012; 56: 908-43.)
Figure 2
Figure 2
Scanning-electron microscope image of Holmium-PLA microspheres (from [73]).
Figure 3
Figure 3
Ligands investigated with radiometals (188Re and 90Y/166Ho/177Lu) for Lipiodol labelling.
Figure 4
Figure 4
188Re-chelates used to label Lipiodol and evaluated in human.
See this image and copyright information in PMC

References

    1. London W. T., McGlynn K. A. Liver cancer. In: Schottenfeld D., Fraumeni J., editors. Cancer Epidemiology and Prevention. 3rd. New York, NY, USA: Oxford University Press; 2006. pp. 763–786.
    1. Ahmed I., Lobo D. N. Malignant tumours of the liver. Surgery (Oxford) 2009;27(1):30–37. doi: 10.1016/j.mpsur.2008.12.005. - DOI
    1. Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Zhu R. X., Seto W.-K., Lai C.-L., Yuen M.-F. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut and Liver. 2016;10(3):332–339. doi: 10.5009/gnl15257. - DOI - PMC - PubMed
    1. Plummer M., de Martel C., Vignat J., Ferlay J., Bray F., Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health. 2016;4(9):e609–e616. doi: 10.1016/S2214-109X(16)30143-7. - DOI - PubMed

Substances